Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

Summary

Chlorogenic acid has demonstrated promising effects in the treatment of glycemic control, obesity, dyslipidemia, insulin secretion, among others. The above mentioned findings show that Chlorogenic acid has an excellent potential for the control of glucose as well as insulin secretion and insulin sensitivity.

Timeline

Start

2015-09

Primary completion

2016-01

Completion

2016-02

Outcome

Mixed primary results

registry MEDIAN Placebo: 5.8 (Standard Deviation 0.3) mmol/L MEDIAN Chlorogenic Acid: 5.5 (Standard Deviation 0.4) mmol/L analysis (superiority or other test); Chlorogenic Acid; p = 0.004 NCT02621060 ↗

registry MEAN Placebo: 9.0 (Standard Deviation 0.8) mmol/L MEAN Chlorogenic Acid: 8.5 (Standard Deviation 0.4) mmol/L analysis (superiority or other test); Chlorogenic Acid; p = 0.084 NCT02621060 ↗

registry MEAN Placebo: 5.8 (Standard Deviation 0.3) Percentage of A1C MEAN Chlorogenic Acid: 5.5 (Standard Deviation 0.4) Percentage of A1C analysis (superiority or other test); Chlorogenic Acid; p = 0.755 NCT02621060 ↗

registry MEAN Placebo: 0.55 (Standard Deviation 0.26) Unitless MEAN Chlorogenic Acid: 0.63 (Standard Deviation 0.25) Unitless analysis (superiority or other test); Chlorogenic Acid; p = 0.03 NCT02621060 ↗

registry MEAN Placebo: 1281 (Standard Deviation 818) Unitless MEAN Chlorogenic Acid: 1133 (Standard Deviation 601) Unitless analysis (superiority or other test); Chlorogenic Acid; p = 0.084 NCT02621060 ↗

registry MEAN Placebo: 2.43 (Standard Deviation 0.88) Unitless MEAN Chlorogenic Acid: 2.30 (Standard Deviation 1.23) Unitless analysis (superiority or other test); Chlorogenic Acid; p = 0.004 NCT02621060 ↗

Publications

• Background van Popele NM, Elizabeth Hak A, Mattace-Raso FU, Bots ML, van der Kuip DA, Reneman RS, Hoeks AP, Hofman A, Grobbee DE, Witteman JC. Impaired fasting glucose is associated with increased arterial stiffness in elderly people without diabetes mellitus: the Rotterdam Study. J Am Geriatr Soc. 2006 Mar;54(3):397-404. doi: 10.1111/j.1532-5415.2005.00614.x.
• Background Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Chitson P, Gareeboo H, Hemraj F, Fareed D, Tuomilehto J, Alberti KG. Impaired fasting glucose or impaired glucose tolerance. What best predicts future diabetes in Mauritius? Diabetes Care. 1999 Mar;22(3):399-402. doi: 10.2337/diacare.22.3.399.
• Background Garber AJ, Handelsman Y, Einhorn D, Bergman DA, Bloomgarden ZT, Fonseca V, Garvey WT, Gavin JR 3rd, Grunberger G, Horton ES, Jellinger PS, Jones KL, Lebovitz H, Levy P, McGuire DK, Moghissi ES, Nesto RW. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. Endocr Pract. 2008 Oct;14(7):933-46. doi: 10.4158/EP.14.7.933. No abstract available.
• Background Whiting DR, Guariguata L, Weil C, Shaw J. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract. 2011 Dec;94(3):311-21. doi: 10.1016/j.diabres.2011.10.029. Epub 2011 Nov 12.
• Background Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, Dagogo-Jack S, Davidson MB, Einhorn D, Garvey WT, Grunberger G, Handelsman Y, Hirsch IB, Jellinger PS, McGill JB, Mechanick JI, Rosenblit PD, Umpierrez G, Davidson MH; American Association of Clinical Endocrinologists. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013 Mar-Apr;19(2):327-36. doi: 10.4158/endp.19.2.a38267720403k242. No abstract available.
• Background Guerrero-Romero F, Rodriguez-Moran M, Perez-Fuentes R, Sanchez-Guillen MC, Gonzalez-Ortiz M, Martinez-Abundis E, Brito-Zurita O, Madero A, Figueroa B, Revilla-Monsalve C, Flores-Martinez SE, Islas-Andrade S, Rascon-Pacheco RA, Cruz M, Sanchez-Corona J. Prediabetes and its relationship with obesity in Mexican adults: The Mexican Diabetes Prevention (MexDiab) Study. Metab Syndr Relat Disord. 2008 Mar;6(1):15-23. doi: 10.1089/met.2007.0020.
• Background American Diabetes Association. Standards of medical care in diabetes-2015 abridged for primary care providers. Clin Diabetes. 2015 Apr;33(2):97-111. doi: 10.2337/diaclin.33.2.97. No abstract available.
• Background Adeney KL, Williams MA, Schiff MA, Qiu C, Sorensen TK. Coffee consumption and the risk of gestational diabetes mellitus. Acta Obstet Gynecol Scand. 2007;86(2):161-6. doi: 10.1080/00016340600994992.
• Background McCarty MF. A chlorogenic acid-induced increase in GLP-1 production may mediate the impact of heavy coffee consumption on diabetes risk. Med Hypotheses. 2005;64(4):848-53. doi: 10.1016/j.mehy.2004.03.037.
• Background Olthof MR, Hollman PC, Katan MB. Chlorogenic acid and caffeic acid are absorbed in humans. J Nutr. 2001 Jan;131(1):66-71. doi: 10.1093/jn/131.1.66.
• Background Renouf M, Marmet C, Giuffrida F, Lepage M, Barron D, Beaumont M, Williamson G, Dionisi F. Dose-response plasma appearance of coffee chlorogenic and phenolic acids in adults. Mol Nutr Food Res. 2014 Feb;58(2):301-9. doi: 10.1002/mnfr.201300349. Epub 2013 Sep 4.
• Zhu H, Chen J, Dong X, Qin X, Li Z. Influence of dihydrocaffeic acid and quinic acid on lung metabolism and function: Implications for dietary interventions. Biochem Biophys Res Commun. 2025 Sep 1;777:152274. doi: 10.1016/j.bbrc.2025.152274. Epub 2025 Jun 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Chlorogenic acid	Small molecule	400 mg	—

Indications